Publications

2026

Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study
Ogbuagu O, Gaur A, McMahon J, Gorgos L, Morales-Ramirez J, Workowski K, Brunetta J, Mponponsuo K, Collins S, VanderVeen L, Zhang N, Huang H, Baeten J, Eron J. Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study. The Lancet Microbe 2026, 7: 101283. PMID: 41720146, DOI: 10.1016/j.lanmic.2025.101283.
Peer-Reviewed Original Research
MeSH Keywords and Concepts
Clinical Pharmacists, Medications, and Contingency Management for Targeting Smoking in HIV Clinics
Edelman E, Deng Y, Dziura J, Nahum-Shani I, Weiss J, Aoun-Barakat L, Bold K, Harsono D, Mistler C, Payne E, Aiudi S, Sigel K, Yager J, Ledgerwood D, Bernstein S. Clinical Pharmacists, Medications, and Contingency Management for Targeting Smoking in HIV Clinics. JAMA Network Open 2026, 9: e2560593. PMID: 41758512, PMCID: PMC12949440, DOI: 10.1001/jamanetworkopen.2025.60593.
Peer-Reviewed Original Research
This study investigates clinical pharmacist-led nicotine replacement therapy (NRT) with contingency management (CM) for reducing smoking in people with HIV, showing CM significantly improved abstinence at 12 weeks and reduced smoking when added after NRT nonresponse.
Full Summary
Lenacapavir treatment–emergent HIV-1 capsid resistance mutations are frequently associated with replication defects
Pennetzdorfer N, Naik V, Demirdjian S, Hendricks M, Jamieson C, Perry J, VanderVeen L, Yant S, Dvory-Sobol H, Ogbuagu O, Gupta S, Margot N, Callebaut C. Lenacapavir treatment–emergent HIV-1 capsid resistance mutations are frequently associated with replication defects. Science Translational Medicine 2026, 18: eaea0947. PMID: 41499523, DOI: 10.1126/scitranslmed.aea0947.
Peer-Reviewed Original Research
MeSH Keywords and Concepts

2025